Treatment Landscape in HR+, HER2- MBC
SABCS 2022 Primary Results From the Randomized Phase II RIGHT Choice Trial: Premenopausal Patients With Aggressive HR+/HER2- Advanced BC Treated With Ribociclib + ET vs. Physician’s Choice Combination Chemo
By
SABCS 2022 Conference Coverage
FEATURING
Yen-Shen Lu
By
SABCS 2022 Conference Coverage
FEATURING
Yen-Shen Lu
Login to view comments.
Click here to Login
Treatment Landscape in HR+, HER2- MBC